AMPD2, OMIM *102771, SPASTIC PARAPLEGIA 63; PONTOCEREBELLAR HYPOPLASIA

Clinical trials for AMPD2, OMIM *102771, SPASTIC PARAPLEGIA 63; PONTOCEREBELLAR HYPOPLASIA explained in plain language.

Never miss a new study

Get alerted when new AMPD2, OMIM *102771, SPASTIC PARAPLEGIA 63; PONTOCEREBELLAR HYPOPLASIA trials appear

Sign up with your email to follow new studies for AMPD2, OMIM *102771, SPASTIC PARAPLEGIA 63; PONTOCEREBELLAR HYPOPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Scientists launch major hunt for clues to mysterious metabolic diseases

Knowledge-focused Recruiting now

This study aims to better understand a group of rare genetic disorders that affect how the body processes certain chemicals, which can cause problems with the brain, blood, kidneys, and immune system. Researchers will observe up to 999 participants, including people with these di…

Matched conditions: AMPD2, OMIM *102771, SPASTIC PARAPLEGIA 63; PONTOCEREBELLAR HYPOPLASIA

Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused

Last updated Mar 18, 2026 14:55 UTC

AMPD2, OMIM *102771, SPASTIC PARAPLEGIA 63; PONTOCEREBELLAR HYPOPLASIA

Get alerted when new AMPD2, OMIM *102771, SPASTIC PARAPLEGIA 63; PONTOCEREBELLAR HYPOPLASIA trials appear

Scientists launch major hunt for clues to mysterious metabolic diseases